Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M R Goldberg

Showing results (81-90 of 92) with videos related to

Pageof 10
Sort By:
International Journal of Clinical Pharmacology and Therapeutics|August 5, 2000
Enalapril in RAPIDISC (wafer formulation): pharmacokinetic evaluation of a novel, convenient formulationLo M-W, J B McCrea, C R Shadle, et al.
Clinical Pharmacology and Therapeutics|March 30, 1999
Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174J B McCrea, A Cribb, T Rushmore, et al.
Applied and Environmental Microbiology|March 7, 2001
Experimental and field studies of Escherichia coli O157:H7 in white-tailed deerJ R Fischer, T Zhao, M P Doyle, et al.
Journal of Clinical Pharmacology|May 12, 2000
Antiplatelet effects of MK-852, a platelet fibrinogen receptor antagonist, in healthy volunteersH E Greenberg, P Wissel, J Barrett, et al.
Hypertension (Dallas, Tex. : 1979)|January 1, 1995
Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patientsM R Goldberg, T E Bradstreet, E J McWilliams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 1, 1995
Phase I clinical study of the recombinant oncotoxin TP40 in superficial bladder cancerM R Goldberg, D C Heimbrook, P Russo, et al.
Clinical Pharmacology and Therapeutics|January 1, 1997
DuP 532, an angiotensin II receptor antagonist: first administration and comparison with losartanM R Goldberg, M W Lo, D D Christ, et al.
Journal of Clinical Pharmacology|January 13, 2000
Rizatriptan, a novel 5-HT1B/1D agonist for migraine: single- and multiple-dose tolerability and pharmacokinetics in healthy subjectsM R Goldberg, Y Lee, K P Vyas, et al.
Biopharmaceutics & Drug Disposition|January 1, 1999
Pharmacokinetics and tolerability of intravenous rizatriptan in healthy femalesY Lee, S J Ermlich, A T Sterrett, et al.
Headache|December 23, 2004
Pharmacokinetics of rizatriptan tablets during and between migraine attacksN R Cutler, S S Jhee, A K Majumdar, et al.
Pageof 10

Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
International Journal of Clinical Pharmacology and Therapeutics|August 5, 2000
Enalapril in RAPIDISC (wafer formulation): pharmacokinetic evaluation of a novel, convenient formulationLo M-W, J B McCrea, C R Shadle, et al.
Clinical Pharmacology and Therapeutics|March 30, 1999
Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174J B McCrea, A Cribb, T Rushmore, et al.
Applied and Environmental Microbiology|March 7, 2001
Experimental and field studies of Escherichia coli O157:H7 in white-tailed deerJ R Fischer, T Zhao, M P Doyle, et al.
Journal of Clinical Pharmacology|May 12, 2000
Antiplatelet effects of MK-852, a platelet fibrinogen receptor antagonist, in healthy volunteersH E Greenberg, P Wissel, J Barrett, et al.
Hypertension (Dallas, Tex. : 1979)|January 1, 1995
Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patientsM R Goldberg, T E Bradstreet, E J McWilliams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 1, 1995
Phase I clinical study of the recombinant oncotoxin TP40 in superficial bladder cancerM R Goldberg, D C Heimbrook, P Russo, et al.
Clinical Pharmacology and Therapeutics|January 1, 1997
DuP 532, an angiotensin II receptor antagonist: first administration and comparison with losartanM R Goldberg, M W Lo, D D Christ, et al.
Journal of Clinical Pharmacology|January 13, 2000
Rizatriptan, a novel 5-HT1B/1D agonist for migraine: single- and multiple-dose tolerability and pharmacokinetics in healthy subjectsM R Goldberg, Y Lee, K P Vyas, et al.
Biopharmaceutics & Drug Disposition|January 1, 1999
Pharmacokinetics and tolerability of intravenous rizatriptan in healthy femalesY Lee, S J Ermlich, A T Sterrett, et al.
Headache|December 23, 2004
Pharmacokinetics of rizatriptan tablets during and between migraine attacksN R Cutler, S S Jhee, A K Majumdar, et al.
Pageof 10